SCM Lifescience was established in 2014 with the vision of 'developing treatment options for difficult to treat diseases to provide a new source of hope for patients and contribute to the welfare of humanity as a whole' using proprietary stem cell isolation technology and stem cell production technology. Through over 10 years of R&D, SCM Lifescience has obtained intellectual property protection for its high-purity stem cell isolation technology(Registered patent in Korea(2008), US(2010), Japan(2012), China(2013), and EU(2014)) and high-purity stem cell production technology(US registered patent(2014)). Based on these technical breakthroughs, high-purity stem cell therapy shall be provided to treat various immunological conditions such as graft-versus-host disease(GVHD), atopic dermatitis, acute pancreatitis, diabetes, and asthma. Our research will also focus on the field of regenerative medicine for technological breakthroughs including the regeneration of skin, cartilage, bone and other various tissues and organs. SCM Lifescience aims to contribute to the advancement of the stem cell sector through its various business areas including high-purity stem cell storage, large-volume culture of stem cell for investigative purposes, and stem cell research. With our proprietary technology, SCM will continue to pursue excellence in the fields of stem cell and regenerative medicine to become an internationally recognized leader in these fields.